^Alfthan, Olof; Andersson, Lennart; Luigi Esposti, Pier; Dorothea Fosså, Sophie; Arne Gammelgaard, Peter; Erik Gjöres, Jan; Isacson, Sune; Rasmussen, Finn; Ruutu, Mirja (1983). “Cisobitan® in Treatment of Prostatic Cancer”. Scandinavian Journal of Urology and Nephrology. 17 (1): 37–43. doi:10.3109/00365598309179778. ISSN0036-5599.
^Chisholm, Geoffrey D. (1985). “Treatment of advanced cancer of the prostate”. Seminars in Surgical Oncology. 1 (1): 38–55. doi:10.1002/ssu.2980010106. ISSN8756-0437.
^Mills, John S; Showell, Graham A (2004). “Exploitation of silicon medicinal chemistry in drug discovery”. Expert Opinion on Investigational Drugs. 13 (9): 1149–1157. doi:10.1517/13543784.13.9.1149. ISSN1354-3784.
^Strindberg, Bengt (1978). “Biochemical Effects of 2, 6-cis-Diphenylhexamethylcyclotetrasiloxane in Man”: 515–520. doi:10.1007/978-1-4613-4018-8_23. Chú thích journal cần |journal= (trợ giúp)
^Krarup T, Rasmussen F, Gammelgaard PA (1978). “Prostatic carcinoma treated with 2,6-cis-diphenylhexamethylcyclotetrasiloxane (Cisobitan)”. Scand. J. Urol. Nephrol. 12 (1): 11–5. PMID345431.